drugset / Trial / NCT02002689
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Timeline
- Start
- 2014-02
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sonidegib | Small molecule | 800 mg | Oral |
Indications
No indication recorded.